IBDEI06G ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6290,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,6290,1,4,0)
 ;;=4^N07.2
 ;;^UTILITY(U,$J,358.3,6290,2)
 ;;=^5015561
 ;;^UTILITY(U,$J,358.3,6291,0)
 ;;=N07.3^^39^446^25
 ;;^UTILITY(U,$J,358.3,6291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6291,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,6291,1,4,0)
 ;;=4^N07.3
 ;;^UTILITY(U,$J,358.3,6291,2)
 ;;=^5015562
 ;;^UTILITY(U,$J,358.3,6292,0)
 ;;=N07.3^^39^446^26
 ;;^UTILITY(U,$J,358.3,6292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6292,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,6292,1,4,0)
 ;;=4^N07.3
 ;;^UTILITY(U,$J,358.3,6292,2)
 ;;=^5015562
 ;;^UTILITY(U,$J,358.3,6293,0)
 ;;=N07.4^^39^446^23
 ;;^UTILITY(U,$J,358.3,6293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6293,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,6293,1,4,0)
 ;;=4^N07.4
 ;;^UTILITY(U,$J,358.3,6293,2)
 ;;=^5015563
 ;;^UTILITY(U,$J,358.3,6294,0)
 ;;=N07.5^^39^446^27
 ;;^UTILITY(U,$J,358.3,6294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6294,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,6294,1,4,0)
 ;;=4^N07.5
 ;;^UTILITY(U,$J,358.3,6294,2)
 ;;=^5015564
 ;;^UTILITY(U,$J,358.3,6295,0)
 ;;=N07.6^^39^446^22
 ;;^UTILITY(U,$J,358.3,6295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6295,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,6295,1,4,0)
 ;;=4^N07.6
 ;;^UTILITY(U,$J,358.3,6295,2)
 ;;=^5015565
 ;;^UTILITY(U,$J,358.3,6296,0)
 ;;=N07.7^^39^446^28
 ;;^UTILITY(U,$J,358.3,6296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6296,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,6296,1,4,0)
 ;;=4^N07.7
 ;;^UTILITY(U,$J,358.3,6296,2)
 ;;=^5015566
 ;;^UTILITY(U,$J,358.3,6297,0)
 ;;=N07.8^^39^446^31
 ;;^UTILITY(U,$J,358.3,6297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6297,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ oth morphologic lesions
 ;;^UTILITY(U,$J,358.3,6297,1,4,0)
 ;;=4^N07.8
 ;;^UTILITY(U,$J,358.3,6297,2)
 ;;=^5015567
 ;;^UTILITY(U,$J,358.3,6298,0)
 ;;=N07.9^^39^446^32
 ;;^UTILITY(U,$J,358.3,6298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6298,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ unsp morphologic lesions
 ;;^UTILITY(U,$J,358.3,6298,1,4,0)
 ;;=4^N07.9
 ;;^UTILITY(U,$J,358.3,6298,2)
 ;;=^5015568
 ;;^UTILITY(U,$J,358.3,6299,0)
 ;;=N08.^^39^446^21
 ;;^UTILITY(U,$J,358.3,6299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6299,1,3,0)
 ;;=3^Glomerular disorders in diseases classified elsewhere
 ;;^UTILITY(U,$J,358.3,6299,1,4,0)
 ;;=4^N08.
 ;;^UTILITY(U,$J,358.3,6299,2)
 ;;=^5015569
 ;;^UTILITY(U,$J,358.3,6300,0)
 ;;=C90.00^^39^447^9
 ;;^UTILITY(U,$J,358.3,6300,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6300,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,6300,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,6300,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,6301,0)
 ;;=C90.01^^39^447^8
 ;;^UTILITY(U,$J,358.3,6301,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6301,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,6301,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,6301,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,6302,0)
 ;;=C90.02^^39^447^7
 ;;^UTILITY(U,$J,358.3,6302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6302,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,6302,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,6302,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,6303,0)
 ;;=E11.29^^39^447^20
 ;;^UTILITY(U,$J,358.3,6303,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6303,1,3,0)
 ;;=3^Type 2 DM w/ Oth Diabetic Kidney Complications
 ;;^UTILITY(U,$J,358.3,6303,1,4,0)
 ;;=4^E11.29
 ;;^UTILITY(U,$J,358.3,6303,2)
 ;;=^5002631
 ;;^UTILITY(U,$J,358.3,6304,0)
 ;;=E11.21^^39^447^19
 ;;^UTILITY(U,$J,358.3,6304,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6304,1,3,0)
 ;;=3^Type 2 DM w/ Diabetic nephropathy
 ;;^UTILITY(U,$J,358.3,6304,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,6304,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,6305,0)
 ;;=E11.22^^39^447^18
 ;;^UTILITY(U,$J,358.3,6305,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6305,1,3,0)
 ;;=3^Type 2 DM w/ Diabetic CKD
 ;;^UTILITY(U,$J,358.3,6305,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,6305,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,6306,0)
 ;;=E10.29^^39^447^17
 ;;^UTILITY(U,$J,358.3,6306,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6306,1,3,0)
 ;;=3^Type 1 DM w/ Oth Diabetic Kidney Complications
 ;;^UTILITY(U,$J,358.3,6306,1,4,0)
 ;;=4^E10.29
 ;;^UTILITY(U,$J,358.3,6306,2)
 ;;=^5002591
 ;;^UTILITY(U,$J,358.3,6307,0)
 ;;=E10.21^^39^447^16
 ;;^UTILITY(U,$J,358.3,6307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6307,1,3,0)
 ;;=3^Type 1 DM w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,6307,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,6307,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,6308,0)
 ;;=E10.22^^39^447^15
 ;;^UTILITY(U,$J,358.3,6308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6308,1,3,0)
 ;;=3^Type 1 DM w/ Diabetic CKD
 ;;^UTILITY(U,$J,358.3,6308,1,4,0)
 ;;=4^E10.22
 ;;^UTILITY(U,$J,358.3,6308,2)
 ;;=^5002590
 ;;^UTILITY(U,$J,358.3,6309,0)
 ;;=D59.3^^39^447^3
 ;;^UTILITY(U,$J,358.3,6309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6309,1,3,0)
 ;;=3^Hemolytic-uremic syndrome
 ;;^UTILITY(U,$J,358.3,6309,1,4,0)
 ;;=4^D59.3
 ;;^UTILITY(U,$J,358.3,6309,2)
 ;;=^55823
 ;;^UTILITY(U,$J,358.3,6310,0)
 ;;=D69.0^^39^447^4
 ;;^UTILITY(U,$J,358.3,6310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6310,1,3,0)
 ;;=3^Henoch-Schoeniein Purpura
 ;;^UTILITY(U,$J,358.3,6310,1,4,0)
 ;;=4^D69.0
 ;;^UTILITY(U,$J,358.3,6310,2)
 ;;=^5002365
 ;;^UTILITY(U,$J,358.3,6311,0)
 ;;=M30.0^^39^447^11
 ;;^UTILITY(U,$J,358.3,6311,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6311,1,3,0)
 ;;=3^Polyarteritis nodosa
 ;;^UTILITY(U,$J,358.3,6311,1,4,0)
 ;;=4^M30.0
 ;;^UTILITY(U,$J,358.3,6311,2)
 ;;=^5011738
 ;;^UTILITY(U,$J,358.3,6312,0)
 ;;=M31.0^^39^447^5
 ;;^UTILITY(U,$J,358.3,6312,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6312,1,3,0)
 ;;=3^Hypersensitivity angiitis
 ;;^UTILITY(U,$J,358.3,6312,1,4,0)
 ;;=4^M31.0
 ;;^UTILITY(U,$J,358.3,6312,2)
 ;;=^60279
 ;;^UTILITY(U,$J,358.3,6313,0)
 ;;=M31.31^^39^447^21
 ;;^UTILITY(U,$J,358.3,6313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6313,1,3,0)
 ;;=3^Wegener's granulomatosis w/ renal involvement
 ;;^UTILITY(U,$J,358.3,6313,1,4,0)
 ;;=4^M31.31
 ;;^UTILITY(U,$J,358.3,6313,2)
 ;;=^5011745
 ;;^UTILITY(U,$J,358.3,6314,0)
 ;;=E85.8^^39^447^1
 ;;^UTILITY(U,$J,358.3,6314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6314,1,3,0)
 ;;=3^Amyloidosis,Other
 ;;^UTILITY(U,$J,358.3,6314,1,4,0)
 ;;=4^E85.8
 ;;^UTILITY(U,$J,358.3,6314,2)
 ;;=^334034
 ;;^UTILITY(U,$J,358.3,6315,0)
 ;;=N28.89^^39^447^6
 ;;^UTILITY(U,$J,358.3,6315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6315,1,3,0)
 ;;=3^Kidney & Ureter Disorders,Oth Specified
 ;;^UTILITY(U,$J,358.3,6315,1,4,0)
 ;;=4^N28.89
 ;;^UTILITY(U,$J,358.3,6315,2)
 ;;=^88007
 ;;^UTILITY(U,$J,358.3,6316,0)
 ;;=E85.4^^39^447^10
 ;;^UTILITY(U,$J,358.3,6316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6316,1,3,0)
 ;;=3^Organ-limited amyloidosis
 ;;^UTILITY(U,$J,358.3,6316,1,4,0)
 ;;=4^E85.4
 ;;^UTILITY(U,$J,358.3,6316,2)
 ;;=^5003017
 ;;^UTILITY(U,$J,358.3,6317,0)
 ;;=M32.14^^39^447^2
 ;;^UTILITY(U,$J,358.3,6317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6317,1,3,0)
 ;;=3^Glomerular disease in systemic lupus erythematosus
 ;;^UTILITY(U,$J,358.3,6317,1,4,0)
 ;;=4^M32.14
 ;;^UTILITY(U,$J,358.3,6317,2)
 ;;=^5011757
